Winstgevend schreef op 4 juli 2019 12:51:
Positive Phase II results in Contrast-induced Nephropathy (CIN)
Positive results from a Phase II investigator-initiated study of RUCONEST®In a DBPC study with 75 patients, RUCONEST® showed a statistically significant effect (p=0.038) in reducing Neutrophil Gelatinase-Associated Lipocalin (NGAL).
Clear results in sub-group of patients (n=30) undergoing PCI.
Median increase in peak urinary NGAL concentration within 48 hours of 1.8 ng/ml compared with an increase of 26.2 ng/ml in the placebo arm (p=0.04).
Median percentage change in the peak urinary NGAL level within 48 hours of
11.3% vs 205.2% in the placebo arm (p=0.001).
Overall patients undergoing invasive procedures requiring high volumes of contrast media experienced a stronger benefit from the RUCONEST® treatment.
Wat een toekomst voor Pharming.......
voor korte EN lange termijn beleggen lijkt mij dit al bewezen.
Succes met het opstapelen...... :-)